GlassScriptPhysician profile
Caitlin G Bunker
NPI 1356039275
$2,101.16
in general payments reported to CMS, 2019-2025
11 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $469 · 2024: $959 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.34 |
| Education | $452.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $405.05 | 2024-2025 | Carvykti, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $309.86 | 2024-2025 | Reblozyl, Breyanzi |
| Incyte Corporation | $296.51 | 2024-2025 | Jakafi |
| Astellas Pharma US INC | $253.98 | 2023 | |
| Pharmacosmos Therapeutics INC. | $245.01 | 2024-2025 | Cosela, Monoferric |
| Merck Sharp & Dohme LLC | $164.23 | 2023-2024 | Keytruda |
| Biolinerx USA, INC. | $117.92 | 2024 | Aphexda |
| Pfizer INC. | $103.06 | 2025 | |
| Lilly USA, LLC | $99.84 | 2023 | |
| Genzyme Corporation | $85.23 | 2025 | |
| Stemline Therapeutics INC. | $20.47 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Bunker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.